Pharmacogenomics in 2023: Big Studies, Big Results, Big Implications, Big Responsibilities

  • Chair(s):

    Andrew Somogyi,
    Professor in Clinical and Experimental Pharmacology,University of Adelaide, Adelaide, Australia

    Ann Daly,
    Professor of Pharmacogenomics,Newcastle University, Newcastle, United Kingdom

  • Session description:

    From Bioinformatics to Machine Learning in Pharmacogenomics to enhance drug effectiveness and safety
    Professor Russ Altman
    Professor of Bioengineering, Genetics, & Medicine, Stanford University, Stanford, The United States of America

    What have we learnt and what will we learn from the UBIQUITIOUS Pharmacogenomics Consortium
    Dr Erika Cecchin
    Experimental and Clinical Pharmacology Unit, National Cancer Institute, Aviano, Italy

    Oral communication speaker - to be confirmed in 2022.

    Predicting and improving response to medicines: lessons learnt from genomes and electronic health records at VUMC

    Professor Sara van Driest
    Vanderbilt University, Nashville, The United States of America

    Machine learning to better understand and predict drug safety
    Professor Masaru Koido
    Yokohama City University, Japan

  • Sponsored by:

    the British Journal of Clinical Pharmacology

  • 00


  • 00


  • 00


  • 00



Leave A Comment